Tinseng liver-protecting tablet as well as preparation method and application thereof

Abstract

The invention relates to the technical field of compatibility of traditional Chinese medicines, in particular to a tetracera tenuifolia liver-protecting tablet as well as a preparation method and application thereof. The tetracera tetracera liver protection tablet is prepared from the following raw materials in parts by mass: 5 to 20 parts of tetracera tetracera, 40 to 60 parts of herba verbenae, 40 to 60 parts of ixeris chinensis, 3 to 15 parts of fructus gardeniae and 23.4 to 61.8 parts of auxiliary materials. The invention provides an oral administration mode for people with alcoholic liver injury. Compared with injections, powder injections and other dosage forms, the pharmaceutical composition has the remarkable advantages of being convenient to use and easy to take. The traditional Chinese medicine composition is especially suitable for people who cannot avoid drinking in long-term life and have alcoholic liver injury, the long-term use requirement of the traditional Chinese medicine composition is met, the medication problem of specific people on liver injury is effectively solved, and a new choice is brought to the field of liver injury treatment.

Description

Technical Field

[0001] This invention relates to the field of traditional Chinese medicine compatibility technology, and in particular to a liver-protecting tablet made from *Xylophora indica* leaves, its preparation method, and its application. Background Technology

[0002] After being absorbed through the gastrointestinal tract, alcohol enters the liver via the portal vein or systemic circulation for metabolism. As the body's core detoxification organ, the liver is highly susceptible to alcohol toxicity, leading to hepatocyte necrosis, fatty degeneration, and even serious diseases such as cirrhosis and liver cancer. Although various liver-protective agents and drugs are available on the market, such as some commonly used antibiotics, anti-tuberculosis drugs, and chemotherapy drugs for tumors, they all have potential hepatotoxicity, further increasing the risk of chemically induced liver injury.

[0003] Therefore, developing a safe, effective, and convenient hangover relief and liver protection tablet is of great practical significance for preventing and improving alcoholic liver damage. Summary of the Invention

[0004] The purpose of this invention is to provide a liver-protecting tablet made from tin leaf vine, its preparation method and application, to reduce the damage of alcohol metabolites to the liver.

[0005] To achieve the above objectives, the present invention provides a liver-protecting tablet made from *Tetrapanax papyriferus*, comprising the following raw materials in parts by weight: 5-20 parts of *Symplocos zebrina*, 40-60 parts of *Verbena officinalis*, 40-60 parts of *Sonchus oleraceus*, 3-15 parts of *Gardenia jasminoides*, and 23.4-61.8 parts of excipients.

[0006] In this invention, the excipients include microcrystalline cellulose, sodium carboxymethyl starch, starch paste, and magnesium stearate.

[0007] In this invention, the mass ratio of microcrystalline cellulose, sodium carboxymethyl starch, starch paste and magnesium stearate is 17-39:2-14:4-8:0.4-0.8.

[0008] In this invention, microcrystalline cellulose has a porous microparticle structure and low water absorption rate, which can form high-hardness tablets after compression, ensuring that the subsequent liver-protecting tablets do not soften in a humid environment.

[0009] In this invention, sodium carboxymethyl starch is used as a disintegrant, which can completely disintegrate the tablet in gastric juice within 3-5 minutes, accelerating the dissolution of active ingredients such as tin leaf vine and gardenia, and ensuring that the liver-protecting tablet takes effect quickly.

[0010] This invention also provides a method for preparing the above-mentioned *Symplocos tinctoria* liver-protecting tablets, comprising the following preparation steps: S1. Dissolve *Symplocos tinctoria*, *Verbena officinalis*, *Sonchus oleraceus*, and *Gardenia jasminoides* in an extractant, extract, and filter to obtain an extract; S2. After concentrating, drying, and pulverizing the extract, add excipients, mix, and compress into tablets to obtain Xiyeteng liver-protecting tablets.

[0011] In this invention, the extractant in S1 comprises an ethanol solution with a mass concentration of 60%-80%.

[0012] In this invention, the extraction temperature in S1 is 75-85℃, the number of extractions is ≥1, and the extraction time for each extraction is 1-2 hours.

[0013] The present invention also provides the application of the above-mentioned *Symplocos tinctoria* liver-protecting tablets or the *Symplocos tinctoria* liver-protecting tablets prepared by the above-mentioned method in the field of health food.

[0014] The present invention has the following beneficial effects: This invention provides a liver-protecting tablet containing *Symplocos tinctoria*, comprising the following raw materials in parts by weight: 5-20 parts of *Symplocos tinctoria*, 40-60 parts of *Verbena officinalis*, 40-60 parts of *Sonchus oleraceus*, 3-15 parts of *Gardenia jasminoides*, and 23.4-61.8 parts of excipients.

[0015] *Datura stramonium* is a plant belonging to the Dilleniaceae family. Its roots and leaves are used medicinally. It is cool in nature and astringent in taste, and is commonly used to clear heat and dampness, detoxify and reduce swelling. It has certain therapeutic effects on damp-heat diarrhea and skin ulcers. Its rich flavonoid and phenolic components can regulate the activity of liver metabolic enzymes, accelerate alcohol decomposition, and protect the liver from alcohol damage.

[0016] Verbena belongs to the Lamiaceae family, and the entire plant can be used medicinally. It is cool in nature and bitter in taste. It has the effects of cooling the blood and dispersing blood stasis, clearing heat and detoxifying, and promoting diuresis and reducing swelling. The flavonoids and terpenoids it contains, after extraction, can activate the liver's detoxification enzyme system and reduce the damage of alcohol metabolites to the liver.

[0017] Sophora flavescens is a plant of the Asteraceae family. It is bitter and cold in nature and contains alkaloids, flavonoids and other components. It can significantly inhibit the liver inflammation response caused by alcohol and promote liver cell repair.

[0018] Gardenia is the fruit of a plant in the Rubiaceae family. It is cold in nature and bitter in taste. It is used to clear heat and relieve irritability, promote diuresis and eliminate dampness, cool the blood and detoxify, and can treat symptoms such as feverish irritability, jaundice, and dark urine. Its main component, geniposide, can promote bile secretion from the liver, accelerate alcohol metabolism and excretion, and protect liver cells; it also has anti-inflammatory and antipyretic effects, which can alleviate inflammatory symptoms.

[0019] This invention utilizes the synergistic effect of four herbs—*Symplocos zebrina* (promotes alcohol metabolism), *Verbena officinalis* (activates detoxification enzymes), *Sonchus oleraceus* (anti-inflammatory), and *Gardenia jasminoides* (promotes bile secretion)—to effectively improve the liver damage caused by alcohol metabolites.

[0020] This invention also provides a method for preparing the above-mentioned *Symplocos tinctoria* liver-protecting tablets, comprising the following preparation steps: S1, dissolving *Symplocos tinctoria*, *Verbena officinalis*, *Sonchus oleraceus*, and *Gardenia jasminoides* in an extractant, extracting and filtering to obtain an extract; S2, concentrating, drying, and pulverizing the extract, adding excipients, mixing, and compressing into tablets to obtain *Symplocos tinctoria* liver-protecting tablets. This invention discloses for the first time an extraction method for extracting anti-alcoholic liver damage effects from *Symplocos tinctoria*, which is simple in process, low in cost, and suitable for large-scale production.

[0021] The technical solution of the present invention will be further described in detail below with reference to the accompanying drawings and embodiments. Attached Figure Description

[0022] Figure 1 This is a histological diagram of mouse liver tissue. in, Figure 1 Image (a) shows the histological changes in liver tissue of mice in the low-dose group. Figure 1 Image (b) shows the histological changes in the liver tissue of mice in the high-dose group. Figure 1 (c) in the figure shows the histological changes of the liver tissue of mice in the blank group. Figure 1 (d) in the figure shows the histological changes of liver tissue in mice in the alcoholic liver injury model group. Figure 1 (e) in the figure shows the histological changes in the liver tissue of mice in the positive group. Figure 1 (f) in the figure shows the histological changes of the liver tissue of mice in the medium-dose group; Figure 2 A graph showing the changes in serum alanine aminotransferase (ALT) levels in mice; Figure 3 The graph shows the changes in serum aspartate aminotransferase (AST) levels in mice. Figure 4 A graph showing the changes in total cholesterol (TC) content in mouse livers; Figure 5 This graph shows the changes in triglyceride (TG) content in mouse liver. Detailed Implementation

[0023] The present invention will be further described below with reference to the accompanying drawings and embodiments. Unless otherwise defined, the technical or scientific terms used in this invention should be understood in their ordinary sense by those skilled in the art. The features mentioned above or in the specific examples mentioned in this invention can be combined arbitrarily, and these specific embodiments are only used to illustrate the invention and are not intended to limit the scope of the invention.

[0024] Example 1 A liver-protecting tablet containing *Tetrapanax papyriferus* (a type of herb) comprises the following ingredients in parts by weight: 5g of *Symplocos zebrina*, 40g of *Verbena officinalis*, 40g of *Sonchus oleraceus*, 3g of *Gardenia jasminoides*, 17.6g of microcrystalline cellulose, 4.4g of sodium carboxymethyl starch, 4.4g of starch paste, and 0.44g of magnesium stearate.

[0025] The preparation method of the above-mentioned *Symplocos tinctoria* liver-protecting tablets includes: S1. Dissolve *Symplocos serrata*, *Verbena officinalis*, *Sonchus oleraceus*, and *Gardenia jasminoides* in a 70% ethanol solution and extract twice at 80°C, with each extraction lasting 1.5 hours, to obtain the extract. S2. Concentrate the extract to a density of 1.2 g / mL. Dry and pulverize the extract, then add microcrystalline cellulose, sodium carboxymethyl starch, starch paste and magnesium stearate in sequence and mix. Then, use a single punch tablet press to compress the mixture into tablets to obtain Xiyeteng liver protection tablets.

[0026] Example 2 A liver-protecting tablet containing *Tetrapanax papyriferus* (a type of herb) comprises the following ingredients in parts by weight: 15g of *Symplocos zebrina*, 50g of *Verbena officinalis*, 50g of *Sonchus oleraceus*, 9g of *Gardenia jasminoides*, 24.8g of microcrystalline cellulose, 6.2g of sodium carboxymethyl starch, 6.2g of starch paste, and 0.62g of magnesium stearate.

[0027] The preparation method of the above-mentioned *Symplocos tinctoria* liver-protecting tablets includes: S1. Dissolve *Symplocos serrata*, *Verbena officinalis*, *Sonchus oleraceus*, and *Gardenia jasminoides* in a 70% ethanol solution and extract twice at 80°C, with each extraction lasting 1.5 hours, to obtain the extract. S2. Concentrate the extract to a density of 1.2 g / mL. Dry and pulverize the extract, then add microcrystalline cellulose, sodium carboxymethyl starch, starch paste and magnesium stearate in sequence and mix. Then, use a single punch tablet press to compress the mixture into tablets to obtain Xiyeteng liver protection tablets.

[0028] Example 3 A liver-protecting tablet containing *Tetrapanax papyriferus* (a type of herb) comprises the following ingredients in parts by weight: 20g of *Symplocos zebrina*, 60g of *Verbena officinalis*, 60g of *Sonchus oleraceus*, 15g of *Gardenia jasminoides*, 38.75g of microcrystalline cellulose, 13.95g of sodium carboxymethyl starch, 7.75g of starch paste, and 0.775g of magnesium stearate.

[0029] S1. Dissolve *Symplocos serrata*, *Verbena officinalis*, *Sonchus oleraceus*, and *Gardenia jasminoides* in a 70% ethanol solution and extract twice at 80°C, with each extraction lasting 1.5 hours, to obtain the extract. S2. Concentrate the extract to a density of 1.2 g / mL. Dry and pulverize the extract, then add microcrystalline cellulose, sodium carboxymethyl starch, starch paste and magnesium stearate in sequence and mix. Then, use a single punch tablet press to compress the mixture into tablets to obtain Xiyeteng liver protection tablets.

[0030] Testing the effects of Xi Ye Teng liver-protecting tablets on serum biochemical indicators in animals with alcoholic liver injury: laboratory animals Thirty-six male BALB / c mice, weighing 20-25g, were used.

[0031] Animal grouping and model establishment: Thirty-six male BALB / c mice were acclimatized for 7 days and then randomly divided into 6 groups (n=6). The study included: a control group (saline), an alcoholic liver injury model group (Beijing Hongxing Erguotou 52%), a positive control group (biphenyl diester 0.10 g / kg), a low-dose group (0.80 g / kg), a medium-dose group (1.60 g / kg), and a high-dose group (3.20 g / kg). Except for the control group, all groups were administered 52% Erguotou liquor (10 ml / kg) by gavage to establish an alcoholic liver injury mouse model. Preliminary experiments showed that successful modeling was indicated by weight loss, loss of appetite, swaying, curling up and collapsing, lethargy, redness and swelling of the reproductive organs in some mice, and dull and disheveled fur. After successful modeling, the control group and the alcoholic liver injury model group were administered the same volume of saline by gavage, the positive control group was administered biphenyl diester by gavage, and the low-dose, medium-dose, and high-dose groups were administered the corresponding concentrations of Xiyeteng liver-protecting tablets by gavage for 10 consecutive days.

[0032] After successful model establishment, mice were gavaged for a final 24-hour period of fasting with no water restriction. Fasting weight was measured in each group. 75% alcohol, sterile syringes, centrifuge tubes, and pipettes were prepared. Mice were anesthetized via intraperitoneal injection with pentobarbital to induce a painless and unconscious state before enucleation and blood collection. Blood was collected in 1.5 mL EP tubes and allowed to stand for 60 minutes until coagulation. The collected blood was then centrifuged for 15 minutes (8000 rpm, -4℃), and the supernatant was collected and pipetteed into a new centrifuge tube for storage at -80℃. Surgical instruments such as scissors and forceps, along with physiological saline, were prepared. Mice were euthanized by cervical dislocation, fixed on a dissecting board, and dissected. The liver, located in the upper abdominal cavity, was gently lifted with forceps, and the liver tissue was carefully cut off with scissors. The tissue was placed in a culture dish containing physiological saline, washed to remove blood, dried with filter paper, weighed, and stored at -80℃. Before using the kit, serum samples do not require special treatment and can be measured directly; for liver tissue samples, a portion of the tissue must be cut from the liver and homogenized by adding 9 volumes of phosphate buffer (0.1 mol / L pH 7.4) at a weight (g):volume (mL) ratio of 1:9.

[0033] Mouse liver index determination: The liver was cleaned with saline solution, the surface moisture was wiped off with filter paper, and then it was weighed on an electronic balance. The results were observed, recorded, and the liver index was calculated.

[0034] ; Liver histopathological observation: Mouse liver tissue was collected and fixed in 4% paraformaldehyde solution. The fixed liver tissue was then dehydrated by passing it through ethanol to remove excess water. After alcohol dehydration, the liver tissue was soaked in xylene for 1.5 hours to make it transparent. The dehydrated and transparent liver tissue blocks were placed in a mold containing melted paraffin wax, and the tissue position was adjusted. The embedding mold was then rapidly cooled and solidified in cold water to form a tissue paraffin block. The blade and paraffin block holder were installed, and the tissue paraffin block was fixed in the paraffin block holder of a microtome. The microtome was rotated to cut the paraffin block into thin slices. The slices were floated on the surface of warm water to flatten them, then lifted and attached to glass slides. Finally, the cell nuclei were stained with hematoxylin and eosin (HE), and the slides were mounted. The histomorphological changes of mouse liver tissue in each group were observed under an optical microscope. Figure 1 It can be seen that in the blank control group, the hepatic sinusoids of mice showed no obvious dilation or compression, the hepatic plates were neatly arranged, and the cell nuclei were round, plump, and clearly defined. In the alcoholic liver injury model group, the liver tissue structure of mice was disordered, the hepatic sinusoids were blurred and obstructed, the hepatocytes were swollen with atrophied nuclei, the cell boundaries disappeared or fused, the cytoplasm was sparse, and the cell nuclei were abundantly aggregated, showing a tendency for cell carcinogenesis, indicating that the model was successful. After drug intervention, the hepatocyte tissue damage in mice in each dose group of *Symplocos tinctoria* extract and the positive control group was significantly improved, the hepatocyte volume decreased, the cell nucleus morphology returned to normal, and the hepatic sinusoids were unobstructed. Compared with the low and high dose groups, the damage in the medium dose group was less severe, the hepatocytes were relatively neatly arranged and intact, and the intercellular spaces were clear, similar to the positive control group. This indicates that *Symplocos tinctoria* extract can prevent and protect against liver damage in ALD mice to a certain extent.

[0035] Biochemical analysis of the effects of Xi Ye Teng liver-protecting tablets on alcoholic liver injury in mice: Analysis of serum alanine aminotransferase (ALT) levels in mice: A standard curve for alanine aminotransferase (ALT) was established by adding 0.1 mol / L phosphate buffer, 2 μmol / mL sodium pyruvate standard solution, ALT matrix buffer, and 2,4-dinitrophenylhydrazine solution to the wells according to the compound concentrations listed in Table 1. The reagents were mixed at 37°C for 20 min, followed by the addition of 200 μL of 0.4 mol / L sodium hydroxide solution. The mixture was then allowed to stand at room temperature for 15 min to obtain the ALT standard curve. The OD values ​​of each well were then measured using a microplate reader at a wavelength of 505 nm. The results are shown below. Figure 2 As shown.

[0036] from Figure 2As can be seen, compared with the blank group, the serum ALT content in the alcoholic liver injury model group mice was significantly increased by 82.47% (P<0.05), indicating that ethanol caused liver damage in mice. After intervention with biphenyl diester and Xi Ye Teng liver-protecting tablets, compared with the model group, the ALT content in the positive group (biphenyl diester 0.10g / kg) was significantly reduced by 40.71%, and the ALT content in the low-dose group (0.80g / kg), medium-dose group (1.60g / kg), and high-dose group (3.20g / kg) of Xi Ye Teng liver-protecting tablets was significantly reduced by 32.47%, 36.39%, and 31.45%, respectively (P<0.05), indicating that the Xi Ye Teng liver-protecting tablets provided by this invention can restore hepatocellular damage caused by alcohol metabolites.

[0037] Table 1. Formulation table for the standard curve of alanine aminotransferase (ALT)

[0038] The results of the alanine aminotransferase (ALT) standard curve test are shown in Table 2.

[0039] Table 2. Results of Alanine aminotransferase (ALT) Standard Curve Test

[0040] The specific (ALT)OD values ​​and changes in ALT activity are shown in Table 3.

[0041] Table 3. Mouse (ALT) OD values ​​and ALT activity data

[0042] Analysis of serum aspartate aminotransferase (AST) levels in mice: A standard curve for aspartate aminotransferase (AST) was established. 0.1 mol / L phosphate buffer, 2 μmol / mL sodium pyruvate standard solution, AST matrix solution, and 2,4-dinitrophenylhydrazine solution were added according to the concentrations listed in Table 4 to obtain reagents for the corresponding well numbers. The reagents were mixed at 37℃ for 20 min, followed by the addition of 200 μL of 0.4 mol / L sodium hydroxide solution. The mixture was then incubated at 25℃ for 15 min to obtain the AST standard curve. Subsequently, the OD values ​​of each well were measured using a microplate reader at a wavelength of 505 nm. The results are shown below. Figure 3 As shown.

[0043] from Figure 3It can be seen that, compared with the blank group, the serum AST content in the alcoholic liver injury model group mice was significantly increased by 305.92% (P<0.05), indicating that ethanol caused liver damage in mice. After administration of biphenyl diester and Xiyeteng liver-protecting tablets, compared with the model group, the AST content in the positive group (biphenyl diester 0.10 g / kg) was significantly reduced by 74.94%, and the AST content in the low-dose group (0.80 g / kg), medium-dose group (1.60 g / kg), and high-dose group (3.20 g / kg) of the Xiyeteng liver-protecting tablet intervention group was significantly reduced by 46.61%, 68.64%, and 76.97%, respectively (P<0.05).

[0044] Table 4. Formulation of Aspartate Aminotransferase (AST) Standard Curve

[0045] The test results of the aspartate aminotransferase (AST) standard curve are shown in Table 5.

[0046] Table 5. Test results of the standard curve of aspartate aminotransferase (AST)

[0047] The specific (AST)OD values ​​and AST activity changes are shown in Table 6.

[0048] Table 6. OD values ​​and AST activity data of mice (AST)

[0049] Analysis of total cholesterol (TC) content in mouse liver: According to the content of each substance in Table 7, add the corresponding amounts of distilled water, calibrator, sample, and working solution to the blank well, calibration well, and sample well, respectively. Then incubate at 37°C for 10 min, and measure the OD value at a wavelength of 500 nm. The results are as follows: Figure 4 As shown.

[0050] from Figure 4 It can be seen that, compared with the blank group, the serum TC content in the alcoholic liver injury model group mice was significantly increased by 86.144% (P<0.05). After intervention with biphenyl diester and Xiyeteng liver-protecting tablets, compared with the model group, the TC content in the positive group (biphenyl diester 0.10 g / kg) was significantly reduced by 38.66%. After intervention with Xiyeteng liver-protecting tablets, the TC content in the low-dose group (0.80 g / kg), medium-dose group (1.60 g / kg), and high-dose group (3.20 g / kg) was significantly reduced by 36.68%, 37.19%, and 35.28%, respectively (P<0.05).

[0051] Table 7. Raw material formulation for the total cholesterol (TC) test.

[0052] The specific (TC)OD values ​​and their TC content are shown in Table 8.

[0053] Table 8. OD values ​​and TC content data of mice (TC)

[0054] Analysis of triglyceride (TG) content in mouse liver: According to the content of each substance in Table 9, add the corresponding amounts of distilled water, calibrator, sample, and working solution to the blank well, calibration well, and sample well, respectively. Then incubate at 37°C for 10 min and measure the OD value at a wavelength of 500 nm. The results are as follows: Figure 5 As shown.

[0055] from Figure 5 It can be seen that, compared with the blank group, the serum TG content in the alcoholic liver injury model group mice was significantly increased by 34.37% (P<0.05). After intervention with biphenyl diester and Xiyeteng liver-protecting tablets, compared with the model group, the TG content in the positive group (biphenyl diester 0.10g / kg) and the low and medium dose groups after Xiyeteng liver-protecting tablet intervention were significantly reduced by 26.65%, 9.48%, and 17.53%, respectively (P<0.05).

[0056] Table 9. Raw material formulation during triglyceride (TG) content testing.

[0057] The specific (TG) OD values ​​and their TG content are shown in Table 10.

[0058] Table 10 (TG) OD values ​​and TG content data

[0059] The biochemical analysis results of the above-mentioned *Xi Ye Teng* liver-protecting tablets on mice with alcoholic liver injury showed that, compared with the blank group, the serum ALT and AST levels and liver tissue TC and TG activities of the alcoholic liver injury model group mice were significantly increased. ALT increased from 16.762 U / L to 30.585 U / L, AST from 30.136 U / L to 122.331 U / L, TC from 2.721 mmol / g to 5.065 mmol / g, and TG from 5.933 mmol / g to 7.972 mmol / g, indicating successful modeling of liver injury in mice. Alcohol significantly increased the serum ALT and AST levels and the liver tissue TC and TG activities in mice. Intervention with biphenyl diester and *Xiye Teng* liver-protecting tablets reduced the elevation of ALT, AST, TC, and TG levels in mice with alcoholic liver injury. Comparing the effects of different drug groups on ALT, the medium-dose group > low-dose group > high-dose group; on AST, the high-dose group > medium-dose group > low-dose group; on TC, the medium-dose group > high-dose group > low-dose group; and on TG, the medium-dose group > low-dose group > high-dose group. Specifically, the medium-dose group showed better efficacy than the high-dose group in ALT, TC, and TG levels. The high-dose group showed better efficacy in AST measurement, indicating that the high-dose group was less effective than the medium-dose group. This is because metabolic enzymes are saturated; the number and activity of drug-metabolizing enzymes are limited. At high doses, enzymes become saturated, drug metabolism slows down, and excessively high blood drug concentrations may lead to drug accumulation and toxicity, affecting efficacy. In experimental mice, among the low, medium, and high-dose groups, the high-dose group showed the most lethargy, lowest weight, most split ends, and even death. The high-dose group showed better results in measuring AST levels because individual mice may respond differently to the drug. Even with strict control of conditions, it is difficult to completely avoid the influence of individual differences during the experiment. Based on a comprehensive evaluation of ALT, AST, TC, and TG levels, the *Xi Ye Teng* liver-protecting tablets provided by this invention can significantly reduce serum ALT, AST, TC, and TG levels in mice with alcoholic acute liver injury. The medium-dose group showed the best effect, demonstrating excellent repair functions against changes in liver cell membrane permeability and fluidity, as well as damage to intracellular mitochondria.

[0060] Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention and not to limit them. Although the present invention has been described in detail with reference to preferred embodiments, those skilled in the art should understand that modifications or equivalent substitutions can still be made to the technical solutions of the present invention, and these modifications or equivalent substitutions cannot cause the modified technical solutions to deviate from the spirit and scope of the technical solutions of the present invention.

Claims

1. A liver-protecting tablet made from *Tinospora sinensis*, characterized in that, The raw materials include the following parts by weight: 5-20 parts of *Symplocos zebrina*, 40-60 parts of *Verbena officinalis*, 40-60 parts of *Sonchus oleraceus*, 3-15 parts of *Gardenia jasminoides*, and 23.4-61.8 parts of excipients.

2. The liver-protecting tablets of *Tetrapanax papyriferus* according to claim 1, characterized in that, The excipients include microcrystalline cellulose, sodium carboxymethyl starch, starch paste, and magnesium stearate.

3. The liver-protecting tablets of *Tetrapanax papyriferus* according to claim 2, characterized in that, The mass ratio of microcrystalline cellulose, sodium carboxymethyl starch, starch paste and magnesium stearate is 17-39:2-14:4-8:0.4-0.

8.

4. A method for preparing a liver-protecting tablet of *Tetrapanax papyriferus* according to any one of claims 1-3, characterized in that, The preparation steps include the following: S1. Dissolve *Symplocos tinctoria*, *Verbena officinalis*, *Sonchus oleraceus*, and *Gardenia jasminoides* in an extractant, extract, and filter to obtain an extract; S2. After concentrating, drying, and pulverizing the extract, add excipients, mix, and compress into tablets to obtain Xiyeteng liver-protecting tablets.

5. The method for preparing a liver-protecting tablet of *Tetrapanax papyriferus* according to claim 4, characterized in that, The extractant in S1 consists of an ethanol solution with a mass concentration of 60%-80%.

6. The method for preparing a liver-protecting tablet of *Tetrapanax papyriferus* according to claim 4, characterized in that, The extraction temperature in S1 is 75-85℃, the number of extractions is ≥1, and the extraction time for each extraction is 1-2 hours.

7. The application of the *Xylophora indica* liver-protecting tablets according to any one of claims 1-3, or the *Xylophora indica* liver-protecting tablets prepared by the preparation method according to any one of claims 4-6, in the field of health food.

Images